Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. This voice experience is generated by AI. Learn more. This ...

We introduce a probabilistic splat-based radiance field framework that replaces the heuristic densification of 3D Gaussian Splatting with end-to-end gradient-based optimization of a volumetric ...

SAN FRANCISCO--(BUSINESS WIRE)--Valinor, a pioneering AI company leveraging advanced machine learning models to increase the probability of clinical trial success by deeply understanding patient ...

Taylor, who joined Recursion through the merger with Exscientia about 18 months ago, described how the combined company aims to address multiple points of failure in drug development. He said ...

You've been using the same phrasing for a while now... Even after I point it out, you return to the same words just a few lines later. The AI's thinking is like a broken record, circling the same spot ...

Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...

Earnings call Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end ...

Patronus AI, the artificial intelligence evaluation startup backed by $20 million from investors including Lightspeed Venture Partners and Datadog, unveiled a new training architecture Tuesday that it ...

Abstract: This paper presents a Bayesian algorithm for joint detection and tracking in a multitarget setting. Raw measurements are processed using the track-before-detect (TBD) framework. We first ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...